Frontage announces an initiative to form Global Drug Discovery Services
Frontage Laboratories has announced an initiative to form Global Drug Discovery Services within the organization. Global Drug Discovery Services will unify all operations in chemistry, biology, ADME/PK and pharmacology at various subsidiaries including Quintara Discovery and ACME Biosciences in the San Francisco Bay Area and BRI in Vancouver, Canada. Through the initiative Frontage can now provide customer-centric, science-driven, end-to-end drug discovery services to its customers around the world.
About Frontage:
Frontage Laboratories, Inc, a full service early-stage CRO with locations in USA and China, has been assisting global biopharmaceutical organizations in their drug development efforts since 2001. Spanning from discovery through late-stage development, its full service offerings include DMPK, bioanalysis using 60 LC-MS/MS instruments, analytical testing, product development, and full biometrics support. Frontage also provides turnkey product development services to generic, innovator and consumer health pharmaceutical companies to support IND, NDA, ANDA, and 505(b)(2) submissions. Frontage has successfully enabled biopharmaceutical and generic companies of all sizes to advance hundreds of molecules through clinical development to commercial launch in global markets.
